1. Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy
   Jianling Bi et al, 2021, Pharmaceuticals CrossRef
2. An integrated approach of network pharmacology, molecular docking, and experimental verification uncovers kaempferol as the effective modulator of HSD17B1 for treatment of endometrial cancer
   Guan-Yu Ruan et al, 2023, Journal of Translational Medicine CrossRef
3. Particles and Prejudice: Nanomedicine Approaches to Reducing Health Disparities in Endometrial Cancer
   Claire E. Rowlands et al, 2023, Small CrossRef
4. Global expression analysis of endometrial cancer cells in response to progesterone identifies new therapeutic targets
   Kristina W. Thiel et al, 2023, The Journal of Steroid Biochemistry and Molecular Biology CrossRef
5. Prolidase-proline oxidase axis is engaged in apoptosis induction by birch buds flavonol santin in endometrial adenocarcinoma cell line
   Lukasz Szoka et al, 2023, Frontiers in Molecular Biosciences CrossRef
6. The DNA Damage Response (DDR) landscape of endometrial cancer defines discrete disease subtypes and reveals therapeutic opportunities
   Xingyuan Zhang et al, 2024, NAR Cancer CrossRef
7. Primary adenosquamous carcinoma of the endometrium with glassy cell features. A diagnostic pitfall as a very rare tumour type in the endometrium
   Selim Sevim et al, 2022, Pathologica CrossRef
8. Utilizing an Endogenous Progesterone Receptor Reporter Gene for Drug Screening and Mechanistic Study in Endometrial Cancer
   Yiyang Li et al, 2022, Cancers CrossRef
9. Role of steroid receptor-associated and regulated protein in tumor progression and progesterone receptor signaling in endometrial cancer
   Jie Liu et al, 2023, Chinese Medical Journal CrossRef
10. The BRD4 inhibitor JQ1 suppresses tumor growth by reducing c-Myc expression in endometrial cancer
    Yingxin Pang et al, 2022, Journal of Translational Medicine CrossRef
11. Characterization of HCI-EC-23 a novel estrogen- and progesterone-responsive endometrial cancer cell line
    Craig M. Rush et al, 2022, Scientific Reports CrossRef
12. A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer
    Sarah E. Paraghamian et al, 2023, Cancer Biology & Therapy CrossRef
13. Detrimental actions of obesity-associated advanced glycation end-products on endometrial epithelial cell proliferation are alleviated by antioxidants
    Jennifer C. Hutchison et al, 2023, Reproductive BioMedicine Online CrossRef
14. The IFN-γ-related long non-coding RNA signature predicts prognosis and indicates immune microenvironment infiltration in uterine corpus endometrial carcinoma
    Chunyan Gu et al, 2022, Frontiers in Oncology CrossRef
15. FGFR2 mutations promote endometrial cancer progression through dual engagement of EGFR and Notch signalling pathways
    Garima Dixit et al, 2023, Clinical and Translational Medicine CrossRef